AngioDynamics, with its disruptive and innovative medical devices, addresses unmet patient needs by elevating the standard of care for chronic and acute disease states in vascular, peripheral vascular, and oncology medicine.
These devices provide healthcare professionals around the world with the vital tools they need to deliver high-quality patient care and improve patient outcomes.
Each day, AngioDynamics and its employees earn the trust of patients and the medical community by being a committed partner that continuously focuses on delivering safer, clinically-relevant and economically-favorable solutions that help improve patient outcomes.
AngioDynamics Announces First Patient Enrolled in NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic Cancer
AngioDynamics Announces Agreement to Sell NAMIC® Fluid Management Business to Medline Industries, Inc. for $167.5 Million
American Urological Association
Date: 03 May, 2019
Time:
Location: Chicago, IL
AngioDynamics Reports Fiscal 2019 Third Quarter Financial Results
AngioDynamics Receives FDA Approval to Initiate NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic Cancer
LATHAM, N.Y.--(BUSINESS WIRE)--May 13, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral ...
AngioDynamics® history is best characterized by innovation and growth. Originally founded in Queensbury, N.Y., U.S., in 1988, AngioDynamics has grown into a NASDAQ-listed public company with a global reach.
USA
International